Post by : Bianca
Haleem
In a decisive move, Pfizer has finalized a $10 billion acquisition of Metsera, effectively concluding a competitive bidding clash with Novo Nordisk that has captivated the pharmaceutical sector this past week.
The New York-based company will offer $86.25 per share in cash, which encompasses $65.60 upfront and a contingent value right of up to $20.65 per share based on future achievements. This deal reflects a premium of 3.69% over Metsera's last closing price on Friday.
This acquisition represents a significant strategic shift for Pfizer, which has been aiming to establish a presence in the rapidly expanding weight-loss drug market, where Novo Nordisk and Eli Lilly currently dominate. Pfizer’s past attempts to create effective obesity treatments did not yield results, making Metsera’s innovative drug pipeline a highly attractive target.
According to analysts, Metsera's top developmental drugs—MET-097i, a GLP-1 injectable, and MET-233i, an amylin-mimicking compound—are projected to achieve combined peak sales of approximately $5 billion. Both drugs operate on metabolic pathways akin to those of Wegovy and Mounjaro, the successful offerings from Novo and Lilly.
Despite Novo Nordisk's last-ditch counteroffer to reclaim leadership in the obesity market, it has ultimately lost out. Metsera’s board noted that Novo’s proposal was fraught with “unacceptably high legal and regulatory risks,” thus opting for Pfizer’s straightforward cash proposition.
The acquisition dramatically escalated from Pfizer’s initial $7.3 billion offer made in September, highlighting the intensifying competition for promising obesity solutions. With the agreement now concluded, Pfizer is placing considerable faith in Metsera’s scientific advancements, hoping to re-enter a highly lucrative market projected to surpass $100 billion globally by the end of this decade.
While Metsera remains in the red as its products are still under development, Pfizer’s extensive resources and global influence could accelerate their approval and commercialization process. This agreement now awaits ratification from Metsera's shareholders, paving the way for one of the year's most noteworthy biotech acquisitions.
English
